Test lets volunteers check Alzheimer's risk, join clinical trials

January 31, 2018 by Bradley J. Fikes, The San Diego Union-Tribune

People interested in helping test Alzheimer's drugs can volunteer and get their cognitive abilities monitored on a new website run by Alzheimer's researchers.

The website, www.aptwebstudy.org , is run by a team including San Diego's Alzheimer's Therapeutic Research Institute.

Those 50 and older are invited to sign up for the screening, said Alzheimer's researcher Dr. Paul Aisen. He directs ATRI, part of the University of Southern California. ATRI, Harvard Medical School and the Cleveland Clinic are collaborating on the initiative.

Called the Alzheimer's Prevention Trials Webstudy, the program is designed to recruit people for , Aisen said. It's funded by a $24.7 million grant from the National Institutes of Health and supported by the Global Alzheimer's Platform Foundation.

The program is designed to identify apparently normal people at higher risk for Alzheimer's, which causes problems with memory, thinking and behavior. These people can then be given experimental therapies before major deterioration sets in.

Its purpose is to provide a large pool of ready volunteers who can quickly be enrolled in any Alzheimer's trial they qualify for, Aisen said. That will speed up the launch of new trials, and hopefully result in faster answers about whether new Alzheimer's therapies work.

Those who sign up will fill out a brief questionnaire about their assessment of their , and then take a 20-minute test to assess those abilities, Aisen said. The test will be repeated over time to look for early signs of deterioration. Participants are asked to repeat it once every three months. They will receive reminders by email.

No exact number has been set, but Aisen said he hopes to get "tens of thousands" of volunteers signed up.

Alzheimer's disease is the sixth-leading cause of death in the United States. It's unique among major killers because there is no approved treatment to prevent the disease or even slow its progression. Existing approved drugs temporarily slow down the deterioration, but don't affect its underlying causes, which are complex and not fully understood.

About 6 million Americans have Alzheimer's or , which can lead to Alzheimer's, according to the National Institutes of Health. If current trends continue, that number is projected to reach 15 million by 2060.

Alzheimer's is the largest single cause of dementia in older adults. A toxic protein called beta amyloid is involved in the disease, with another protein, called tau.

While there's still a need for more basic research into how Alzheimer's starts and develops, understanding of the disease has increased greatly over the last several years, Aisen said. That has led to a profusion of clinical trials for various drugs, including nasally inhaled insulin, nicotine patches and other drugs specifically developed for Alzheimer's. That means more participants are needed.

There's no geographic restriction on applying, but those taking part in clinical trials must be willing to travel to one of 35 sites in the United States where they can be tested in person. More sites may be added later.

In-person testing will involve either a brain scan or a spinal tap to look for beta amyloid, he said. That will only be done for participants whose tests indicate they might benefit from a clinical trial. This makes the testing more efficient, and reduces expenses.

"If we see that your scores are steadily declining, even though you have absolutely no symptoms, that tells us a lot about the risk of there being amyloid in your brain," he said.

Those chosen will be given another consent form, which will explain the study's purpose, potential benefits and risks.

Participant information is confidential and protected, Aisen said. While the program needs to reach individuals through an email address, their identifying information is not given to anyone not working with the program. Participants can still take part in the program without volunteering for clinical . The online test data will be aggregated for research, but individual identities won't be revealed.

Moreover, if participants get cold feet after signing up, they can delete their information, Aisen said.

The program has been planned to last five years with current funding, he said. After that, the goal is to make the program self-supporting, by contracting directly with sponsors of clinical studies.

Explore further: The next decade could bring a breakthrough in Alzheimer's research, expert says


Related Stories

The next decade could bring a breakthrough in Alzheimer's research, expert says

October 11, 2017
Effective treatments for Alzheimer's disease are five to 10 years away, according to a Keck School of Medicine of USC researcher.

Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial

January 25, 2018
A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer's disease developed by Eli Lilly that targets amyloid plaques, did not significantly ...

Researchers discover what may be earliest stage of Alzheimer's disease

June 13, 2017
Older adults with elevated levels of brain-clogging plaques—but otherwise normal cognition—experience faster mental decline suggestive of Alzheimer's disease, according to a new study led by the Keck School of Medicine ...

New Alzheimer's study aims to delay or prevent symptoms

June 17, 2016
USC researchers announced Tuesday they will test a promising drug aimed at preventing or delaying the symptoms of Alzheimer's disease.

Population of Americans with Alzheimer's will more than double by 2060, study shows

December 7, 2017
About 15 million Americans will have either Alzheimer's dementia or mild cognitive impairment by 2060, up from approximately 6.08 million this year, according to a new study by researchers at the UCLA Fielding School of Public ...

Positive results from Alzheimer's drug in Phase 1 clinical trial extension

November 3, 2017
The pharmaceutical company Biogen has today announced the results of an extended phase 1b clinical trial of the potential Alzheimer's disease drug, aducanumab. Results from the extended early stage trial, were announced today ...

Recommended for you

Data detectives shift suspicions in Alzheimer's to inside villain

February 20, 2018
The mass pursuit of a conspicuous suspect in Alzheimer's disease may have encumbered research success for decades. Now, a new data analysis that has untangled evidence amassed in years of Alzheimer's studies encourages researchers ...

Not being aware of memory problems predicts onset of Alzheimer's disease

February 15, 2018
Doctors who work with individuals at risk of developing dementia have long suspected that patients who do not realize they experience memory problems are at greater risk of seeing their condition worsen in a short time frame, ...

Researchers successfully reverse Alzheimer's disease in mouse model

February 14, 2018
A team of researchers from the Cleveland Clinic Lerner Research Institute have found that gradually depleting an enzyme called BACE1 completely reverses the formation of amyloid plaques in the brains of mice with Alzheimer's ...

Poor fitness linked to weaker brain fiber, higher dementia risk

February 14, 2018
Scientists have more evidence that exercise improves brain health and could be a lifesaving ingredient that prevents Alzheimer's disease.

Compound prevents neurological damage, shows cognitive benefits in mouse model of Alzheimer's disease

February 7, 2018
The supplement nicotinamide riboside (NR) – a form of vitamin B3 – prevented neurological damage and improved cognitive and physical function in a new mouse model of Alzheimer's disease. The results of the study, conducted ...

Positive attitudes about aging reduce risk of dementia in older adults

February 7, 2018
Research has shown that older persons who have acquired positive beliefs about old age from their surrounding culture are less likely to develop dementia. This protective effect was found for all participants, as well as ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.